Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Quest Diagnostics, Genalyte


Quest Diagnostics this week released two tests for the diagnosis of rheumatoid arthritis based on the 14-3-3eta protein.

One test consists 14-3-3eta protein alone, while the other includes this protein along with established RA markers cyclic citrullinated peptide antibodies and rheumatoid factor. The tests, are intended for the diagnosis of RA, and early diagnosis of the disease in particular, the company said.

Quest licensed US rights to the 14-3-3eta protein from Canadian biotech firm Augurex (see related story this issue).

Genalyte this week released its MT-ADA anti-drug antibody immunogenicity assay for drug development.

The assay is intended for detecting unwanted immune responses to drugs by measuring the presence of anti-drug antibodies. The test allows for simultaneous detection of eight antibody classes and can be used for both mouse and human samples, the company said.